Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Conditions
Advanced Solid Tumor · Metastatic Solid Tumor · Refractory Solid Tumor · Cancer · Lung Cancer · Triple Negative Breast Cancer · Breast Neoplasms · Neuroendocrine Tumors · Neuroendocrine Carcinoma · RB1 Gene Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Florida Cancer Specialists, Sarasota, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
START Midwest, Grand Rapids, Michigan, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
UH Seidman Cancer Center, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
START Mountain, West Valley City, Utah, United States